Osimertinib Proves Frontline Status in EGFR+ Advanced NSCLC
Jonathan W. Goldman, MD, discusses the use of osimertinib in the first line setting for patients with non–small cell lung cancer.
Strategies for Managing Adverse Events of Osimertinib for EGFR+ NSCLC
Jonathan W. Goldman, MD, discusses management of the most common adverse events associated with osimertinib in patients with non–small cell lung cancer.